Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis
Francesca Della Casa,Antonio Vitale,Rosa Maria Pereira,Silvana Guerriero,Gaafar Ragab,Giuseppe Lopalco,Marco Cattalini,Irene Mattioli,Paola Parronchi,Maria Pia Paroli,Emanuela Del Giudice,Carla Gaggiano,Marília A Dagostin,Valeria Albano,Mahmoud M Soliman,Sergio Colella,Giuseppe Nascimbeni,Jurgen Sota,Isabele P B Antonelli,Giovanni Alessio,Valeria Caggiano,Abdurrahman Tufan,Rana Hussein Amin,Maria Tarsia,Mahmoud Ghanema,Florenzo Iannone,Francesca Ricci,Francesco La Torre,Ewa Więsik-Szewczyk,Edoardo Conticini,Stefano Gentileschi,Rosanna Dammacco,Rolando Cimaz,Bruno Frediani,Anna Abbruzzese,Piero Ruscitti,Gian Marco Tosi,Heitor F Giordano,Alessandro Conforti,Alberto Balistreri,Donato Rigante,Luca Cantarini,Claudia Fabiani
DOI: https://doi.org/10.1007/s40123-022-00466-2
Abstract:Introduction: This article points out the design, methods, development and deployment of the international registry promoted by the AutoInflammatory Disease Alliance (AIDA) Network with the aim to define and assess paediatric and adult patients with immune-mediated scleritis. Methods: This registry collects both retrospective and prospective real-world data from patients with non-infectious scleritis through the Research Electronic Data Capture (REDCap) tool and aims to promote knowledge and real-life evidence from patients enrolled worldwide; the registry also allows the collection of standardised data, ensuring the highest levels of security and anonymity of patients' data and flexibility to change according to scientific acquisitions over time. The communication with other similar registries has been also ensured in order to pursue the sustainability of the project with respect to the adaptation of collected data to the most diverse research projects. Results: Since the launch of the registry, 99 centres have been involved from 20 countries and four continents. Forty-eight of the centres have already obtained a formal approval from their local ethics committees. At present, the platform counts 259 users (95 principal investigators, 160 site investigators, 2 lead investigators, and 2 data managers); the platform collects baseline and follow-up data using 3683 fields organised into 13 instruments, including patient's demographics, history, symptoms, trigger or risk factors, therapies and healthcare utilization. Conclusions: The development of the AIDA International Registry for patients with non-infectious scleritis will allow solid research on this rare condition. Real-world evidence resulting from standardised real-life data will lead to the optimisation of routine clinical and therapeutic management, which are currently limited by the rarity of this ocular inflammatory condition.